New model could predict deadly liver failure after surgery

NCT ID NCT06366048

Recruiting now Knowledge-focused Sponsor: National Natural Science Foundation of China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the amount of healthy liver removed during surgery can predict liver failure afterward. Researchers will create a risk model based on 1,600 patients who had liver surgery for cancer. The goal is to help doctors identify high-risk patients before surgery and improve safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could give surgeons a simple tool to predict which patients are at high risk of liver failure after surgery, helping them plan safer operations.
What could go wrong: This is an observational study, not a treatment trial. The model may not be accurate for all patients or hospitals, and it does not test any new drug or therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma intrahepatic cholangiocarcinoma liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER FAILURE

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, Mengchao Hepatobiliary Hospital of Fujian Medical University
RECRUITING

Shenzhencun, Shanghai Municipality, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
RECRUITING

Fujian, Shanghai Municipality, China
The Third Affiliated Hospital of Naval Medical University
RECRUITING

Shanhai, Shanghai Municipality, 201800, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.